Project Grant R21CA302979
Award Date
7/3/25
Completion Date
6/30/27
Dollars Obligated
$415K
Federal Agency
National Cancer Institute
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This $1,108,391.72 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to define the most therapeutically relevant chimeric antigen receptor (CAR) T cell subsets for treating large B cell lymphoma (LBCL) and overcome immune suppression mechanisms that limit CAR T cell efficacy. The funded project will use a systems biology approach to analyze patient data and pinpoint optimal CAR T cell characteristics for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $604,627 to the Trustees of Dartmouth College to conduct research aimed at deconvoluting the heterogeneity of chimeric antigen receptor (CAR) T cells in order to engineer durable antitumor immunity. The research project, which runs from January 1, 2025 to December 31, 2029, will use dynamic lineage recording to understand how individual CAR T cell subsets behave in vivo and...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $140,433 to The Leland Stanford Junior University to generate CD19.28Z chimeric antigen receptor (CAR) T cells in vivo using a novel "Programmable Antibody-mediated Cellular Knock-in of T cells" (PACK-IT) system. The goal is to develop a more effective and accessible CAR-T cell therapy for B-cell malignancies by eliminating the ex vivo manufacturing process. The project...
The National Cancer Institute (NCI) awarded a $1,477,396 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope in Duarte, CA. The grant, awarded on December 1, 2024, supports a novel approach to enhance the efficacy and durability of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The project involves selecting cytomegalovirus (CMV)-specific T cells, modifying them with a...
This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Grant Program 93.395 Cancer Treatment Research (CFDA 93.395), is funding the development of novel chimeric antigen receptor (CAR) T-cell therapies targeting the U5 small nuclear ribonucleoprotein (U5 snRNP) complex for the treatment of acute myeloid leukemia (AML). The $402,600 award, granted on Apr 3, 2025, supports research by the Sloan-Kettering Institute for Cancer Research to: (1) test the efficacy and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $169,329 to Wake Forest University Health Sciences to develop a novel B cell receptor (BCR) transgenic mouse model to study glycan-specific B cells and their role in tumor-associated carbohydrate antigen (TACA) responses. The objectives are to characterize the potential for these transgenic B cells to engage in antibody-dependent and independent anti-tumor mechanisms, as well...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), awarded a $398,997 Project Grant to Immunogenik, Inc. in Gainesville, Florida. The grant supports the development and evaluation of a "3-in-1" Chimeric Antigen Receptor (CAR) T-cell therapy to enhance cancer treatment. The project aims to overcome limitations of current cancer therapies by targeting tumor-associated myeloid cells, which play a key role in cancer...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower (CFDA 93.398) program, provides $176,040 to The General Hospital Corporation (Massachusetts General Hospital) from July 1, 2025 to June 30, 2027. The project aims to develop new strategies to engineer CAR-T cell therapies that can overcome the cancer cell glycocalyx barrier for improved immunotherapy, particularly for solid tumors like breast cancer and glioblastoma. Key objectives include...